XML 54 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Organization, Description of Business and Summary of Significant Accounting Policies - Schedule of Biopharmaceutical and Other Revenues (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Disaggregation of Revenue [Line Items]    
Total revenue $ 67,783 $ 36,703
Development services    
Disaggregation of Revenue [Line Items]    
Total revenue 5,931 566
Provision of data    
Disaggregation of Revenue [Line Items]    
Total revenue 765 0
Milestones    
Disaggregation of Revenue [Line Items]    
Total revenue 350 0
Contract manufacturing    
Disaggregation of Revenue [Line Items]    
Total revenue 1,539 0
Contract testing    
Disaggregation of Revenue [Line Items]    
Total revenue 239 0
Biopharmaceutical and other revenue    
Disaggregation of Revenue [Line Items]    
Total revenue $ 8,824 $ 566